Navigation Links
Cardiva Medical, Inc. Appoints Two New Officers: Malcolm Farnsworth as Vice President of Finance and Chief Financial Officer and Tara Zerby as Vice President of Business Development and Marketing

MOUNTAIN VIEW, Calif., Jan. 17 /PRNewswire/ -- Cardiva Medical, Inc., a privately held medical device company and developer of the Boomerang Catalyst(TM) System is pleased to announce the addition of two officers to their management team. Malcolm Farnsworth joins Cardiva as Vice President of Finance and Chief Financial Officer. Tara Zerby joins Cardiva as Vice President of Business Development and Marketing.

"We are very excited to have Malcolm and Tara join Cardiva during this exciting stage in the company," says Augustine Lien, Chairman and CEO. "Their expertise in the medical device industry will be beneficial in the growth of our company."

Malcolm Farnsworth joined Cardiva in January 2008. Previously, Mr. Farnsworth served as Executive Vice President and Chief Financial Officer at POINT Biomedical Corporation, a specialty pharmaceutical company developing pharmaceutical imaging agents to detect coronary artery disease. Prior to that, he served as Vice President of Finance and Chief Financial Officer at Gynecare, Inc., a medical device company, that was acquired by Johnson & Johnson after its IPO in 1996. Before that he served as Vice President of Finance and Chief Financial Officer at Origin Medsystems, a minimally invasive surgical device company that was acquired by Eli Lilly and merged into Guidant. Mr. Farnsworth holds an M.B.A. degree from the Haas School, University of California at Berkeley and a B.S. degree in Business and Economics from Lehigh University.

Tara L. Zerby joined Cardiva in November 2007. Ms. Zerby brings with her over 25 years of experience in sales, marketing and management in the medical device industry. Prior to joining Cardiva, she served as Vice President and General Manager of RTI-Cardiovascular, formerly the Alabama Tissue Center. Ms. Zerby operated her own consulting firm, assisting start-up medical device companies. She was also the executive Director of Marketing and Clinical Applications for Stereotaxis, Inc., Business Unit Director, Surgical Systems and Director of Global Sales for Cryocath Technologies. Ms. Zerby holds an M.B.A. from University of Wisconsin, an M.A. from Georgia State and a B.A. from Wake Forest.

About Cardiva Medical, Inc.

Founded in July 2002, and headquartered in Mountain View, Calif., Cardiva Medical, Inc. is a privately held medical company focused on developing and commercializing vascular access site management and closure devices with unsurpassed safety and ease-of-use. Cardiva's first product, the Boomerang Wire System, was approved in EU countries and in the US in 2004. Cardiva's second-generation product, the Boomerang Catalyst System, was approved in March 2007 and launched in July 2007. The enhanced Boomerang Catalyst, trade named as "Boomerang Catalyst II System" received 510(K) clearance in September 2007 and launched in January 2008. Cardiva was selected by Frost & Sullivan as the recipient of the 2006 Frost & Sullivan Award for Entrepreneurial Company in the U.S. angioplasty and vascular closure devices market. For additional information about Cardiva Medical, Inc. see our website at

Cardiva, Boomerang and Boomerang Catalyst System are trademarks/registered trademarks of Cardiva Medical, Inc.

Media Contact:

Glenn Foy, President

Cardiva Medical, Inc.

Phone: 650.964.8900, x 215

Fax: 650.964.8911

SOURCE Cardiva Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Cardiva Medical, Inc. to Present at the UBS 2007 Global Life Science Conference With the Announcement of FDA 510(K) Clearance of its Newest Device: The Boomerang Catalyst II System(TM)
2. Cardiva Medical, Inc. to Present at the UBS 2007 Global Life Science Conference With the Announcement of FDA 510(K) Clearance of its Newest Device: The Boomerang Catalyst II System(TM)
3. Medical, technological advances prompt updating of nuclear medicine technologists scope of practice
4. Thermage, Inc. Announces Distribution Agreement With Eclipse Medical, Ltd.
5. Medical, Behavioral Woes Can Drive Dogs to Bite
6. ReBuilder Medical Technologies, Inc. Announces UK Demand for Safe Molluscum Contagiosum Treatment Leads to Distribution Agreement with UFFE Medical, LTD. Expected 10% Sales Increase.
7. Sedgwick CMS and UnitedHealth Group to Develop Integrated Disability, Medical, Workers Compensation and Leave Administration Services for Employers
8. Emmaus Medical, Inc. Enters Into Sub-License Agreement for Treatment of Short Bowel Syndrome
9. XCPT(TM) Patient Engagement and Communication Software Signs Representation Agreement with Lifecore Biomedical, Inc. (Nasdaq: LCBM)
10. Gary Tschautscher of Nonin Medical, Inc. Receives CEO of 2007 for North American Patient Monitoring From Frost & Sullivan
11. WorldHeart Appoints David Pellone Chief Financial Officer
Post Your Comments:
(Date:12/1/2015)... , ... December 01, 2015 , ... It’s official: Tattoo ... tattoo — a number even greater among Millennials (a whopping one in three aged ... and more people who are dissatisfied with their ink. In fact, RealSelf , ...
(Date:12/1/2015)... Illinois (PRWEB) , ... December 01, 2015 , ... ... and share medical images have been lifted as IMAGE Information Systems launches MED-TAB™ ... Society of North America Annual Meeting from November 29 to December 4, 2015. ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... in the United States. Podiatrists are well aware that psychology-based patient non-compliance (disobedience ... are often catastrophic contributors to diseases of the diabetic foot. The American ...
(Date:12/1/2015)... ... 2015 , ... The importance of volumetric breast density assessment ... numerous abstracts accepted for presentation here, at the 101st Annual Radiology Society of ... use of Volpara Solutions’ quantitative breast imaging software tools for providing breast imaging ...
(Date:12/1/2015)... ... 2015 , ... For many X-rays taken at hospitals, doctors’ ... by the radiologist. The marking utensils are so small, however, they are difficult ... way to alleviate this problem. , He developed the patent-pending MARK N SHOW ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... LOS ANGELES , Dec. 1, 2015 ... and development company specializing in oncology, today announced that ... for the company,s pivotal global Phase 3 clinical trial ... sarcoma (STS). Enrollment was originally estimated to be completed in ... trial being conducted under a Special Protocol Assessment from ...
(Date:12/1/2015)... , Dec. 1, 2015   MabVax Therapeutics ... development company, announces it has filed an Investigational New ... Administration (FDA) for the Company,s lead fully human antibody ... FDA acceptance, MabVax plans to initiate the Phase I ... --> --> The planned Phase I ...
(Date:12/1/2015)... CHESTERBROOK, Pa. , Dec. 1, 2015 /PRNewswire/ ... leader, announced the launch of CareFront, a first-of-its-kind ... of patients diagnosed with cancer. Designed to be ... newly diagnosed cancer patients with resources for their ... costs. The program also offers tools to help ...
Breaking Medicine Technology: